Morpholino

MO6-dmd

ID
ZDB-MRPHLNO-130614-1
Name
MO6-dmd
Previous Names
  • dystrophin anti-sense 1 (1)
Target
Sequence
5' - GCCATGACATAAGATCCAAGCCAAC - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
Translation-blocking MO.
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO6-dmd
No data available
Phenotype
Phenotype resulting from MO6-dmd
Phenotype of all Fish created by or utilizing MO6-dmd
Phenotype Fish Conditions Figures
muscle broken, abnormal dmdta222a/ta222a + MO1-dmd + MO6-dmd standard conditions Fig. 2 with image from Johnson et al., 2013
whole organism pax7b expression amount, ameliorated AB + MO1-dmd + MO6-dmd chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 2 from Spreafico et al., 2021
alpha-tubulin acetylation occurrence, ameliorated AB + MO1-dmd + MO6-dmd chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 5 from Spreafico et al., 2021
skeletal muscle lesioned, abnormal AB + MO1-dmd + MO6-dmd control Fig. 2 from Spreafico et al., 2021
whole organism pax7b expression increased amount, abnormal AB + MO1-dmd + MO6-dmd control Fig. 2 from Spreafico et al., 2021
whole organism mylpfa expression decreased amount, abnormal AB + MO1-dmd + MO6-dmd control Fig. 2 from Spreafico et al., 2021
whole organism mylpfa expression amount, ameliorated AB + MO1-dmd + MO6-dmd chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 2 from Spreafico et al., 2021
skeletal muscle lesioned, ameliorated AB + MO1-dmd + MO6-dmd chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 2 from Spreafico et al., 2021
whole organism pax3b expression amount, ameliorated AB + MO1-dmd + MO6-dmd chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 2 from Spreafico et al., 2021
whole organism hdac8 expression increased amount, abnormal AB + MO1-dmd + MO6-dmd standard conditions Fig. 2 from Spreafico et al., 2021
alpha-tubulin acetylation decreased occurrence, abnormal AB + MO1-dmd + MO6-dmd control Fig. 5 from Spreafico et al., 2021
whole organism pax3a expression amount, ameliorated AB + MO1-dmd + MO6-dmd chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 2 from Spreafico et al., 2021
whole organism pax3a expression increased amount, abnormal AB + MO1-dmd + MO6-dmd control Fig. 2 from Spreafico et al., 2021
whole organism pax7a expression amount, ameliorated AB + MO1-dmd + MO6-dmd chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 2 from Spreafico et al., 2021
whole organism pax3b expression increased amount, abnormal AB + MO1-dmd + MO6-dmd control Fig. 2 from Spreafico et al., 2021
muscle cell increased width, abnormal AB + MO1-dmd + MO6-dmd control Fig. 5 from Spreafico et al., 2021
whole organism pax7a expression increased amount, abnormal AB + MO1-dmd + MO6-dmd control Fig. 2 from Spreafico et al., 2021
muscle cell increased width, ameliorated AB + MO1-dmd + MO6-dmd chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 5 from Spreafico et al., 2021
whole organism crebbpb expression decreased amount, abnormal WT + MO1-dmd + MO6-dmd standard conditions Fig. 1 with image from Bajanca et al., 2017
somite border dmd expression absent, abnormal WT + MO1-dmd + MO6-dmd standard conditions Fig. 1 with image from Bajanca et al., 2017
whole organism ep300b expression decreased amount, abnormal WT + MO1-dmd + MO6-dmd standard conditions Fig. 1 with image from Bajanca et al., 2017
myotome broken, abnormal WT + MO1-dmd + MO6-dmd standard conditions Fig. 3 with image from Johnson et al., 2013
whole organism ep300a expression decreased amount, abnormal WT + MO1-dmd + MO6-dmd standard conditions Fig. 1 with image from Bajanca et al., 2017
skeletal muscle cell disorganized, abnormal WT + MO1-dmd + MO6-dmd standard conditions Fig. 1 with image from Bajanca et al., 2017
muscle broken, abnormal WT + MO1-dmd + MO6-dmd standard conditions Fig. 2 with imageFig. 3 with image from Johnson et al., 2013
whole organism fstb expression decreased amount, abnormal WT + MO1-dmd + MO6-dmd chemical treatment by environment: trichostatin A Fig. 1 with image from Bajanca et al., 2017
skeletal muscle cell organization quality, ameliorated WT + MO1-dmd + MO6-dmd chemical treatment by environment: trichostatin A Fig. 1 with image from Bajanca et al., 2017
whole organism crebbpa expression decreased amount, abnormal WT + MO1-dmd + MO6-dmd chemical treatment by environment: trichostatin A Fig. 1 with image from Bajanca et al., 2017
muscle broken, abnormal zf13Tg + MO1-dmd + MO6-dmd standard conditions Fig. 2 with imageFig. 3 with imageFig. 4 with image from Johnson et al., 2013
myotome broken, abnormal zf13Tg + MO1-dmd + MO6-dmd standard conditions Fig. 3 with imageFig. 4 with image from Johnson et al., 2013
muscle broken, abnormal zf13Tg + MO1-dmd + MO6-dmd chemical treatment: pharmaceutical Fig. 5 with image from Johnson et al., 2013
myotome neutrophil amount, ameliorated zf13Tg + MO1-dmd + MO6-dmd (AB) chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 3 from Spreafico et al., 2021
myotome neutrophil increased amount, abnormal zf13Tg + MO1-dmd + MO6-dmd (AB) control Fig. 3 from Spreafico et al., 2021
muscle broken, abnormal zf13Tg + MO6-dmd standard conditions Fig. 1 with image from Johnson et al., 2013
Citations